B1344
B1344 has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jun 24, 2025: “B1344 ameliorates non-alcoholic steatohepatitis in HFCD-HF/G-induced mice: exploring the therapeutic efficacy and mechanism of a novel FGF21 analogue”.
1 paper studies it4 findingsUpdated
- 1 lab in 1 country
- Funder: National Natural Science Foundation of China
- Animals1
What did studies of B1344 find?
4Studies of B1344 measured 4 outcomes; the most studied are non-alcoholic steatohepatitis (1 study), fgf21 resistance (1) and insulin resistance (1).
Non-alcoholic steatohepatitis
downin mice1
1 study
Non-alcoholic steatohepatitis
downin mice1
B1344 decreases non-alcoholic steatohepatitis in mice.
“B1344 demonstrates robust efficacy against NASH in HFCD-HF/G-induced mice.”
Animalsin HFCD-HF/G-induced mice8 weeks
European journal of pharmacology
FGF21 resistance
downin mice1
1 study
FGF21 resistance
downin mice1
B1344 decreases fgf21 resistance in mice.
“Notably, it restored AT dysfunction and alleviated FGF21 resistance.”
Animalsin HFCD-HF/G-induced miceadipose tissue8 weeks
European journal of pharmacology
Insulin resistance
downin mice1
1 study
Insulin resistance
downin mice1
B1344 decreases insulin resistance in mice.
“Systemic insulin resistance and downsream signaling in liver, muscle and AT was improved by B1344.”
Animalsin HFCD-HF/G-induced mice8 weeks
European journal of pharmacology
Hepatic damages
downin mice1
1 study
Hepatic damages
downin mice1
B1344 decreases hepatic damages in mice.
“B1344 attenuated HFCD-HF/G-induced metabolic disorder and hepatic damages.”
Animalsin HFCD-HF/G-induced miceliver8 weeks
European journal of pharmacology